PRO TCR 401
Alternative Names: HA-1 TCR T for Leukemia Relapse Post-BMT - PromiCell Therapeutics/Fred Hutchingson Cancer Research Center; HA-1 TCR T therapy PromiCell Therapeutics/Fred Hutchingson Cancer Research Center; PRO TCR-401Latest Information Update: 03 Jul 2025
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Fred Hutchinson Cancer Research Center; PromiCell Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 03 Jul 2025 PromiCell Therapeutics plans a phase I trial for Acute myeloid leukaemia in 2025 (PromiCell Therapeutics website, July 2025)